Three selected reports examine pramlintide alongside insulin in diabetes. Two are year-long adjunctive-treatment trials; the third evaluates an experimental automated insulin-and-pramlintide system and is not interchangeable with routine labeled treatment.123
Bottom line from this bounded source set
Year-long trials reported modest HbA1c and weight changes compared with placebo added to insulin. Nausea was common. The automated-delivery study met its glucose-control noninferiority objective but did not improve its emotional-burden endpoint.123
Reviewed study record
Type 1 diabetes: year-long adjunctive trial
Design
Randomized, double-blind, placebo-controlled trial over 52 weeks alongside insulin.1
The reported active groups had HbA1c reductions of 0.29–0.34 percentage points versus 0.04 with placebo. Weight declined by 0.4 kg versus a 0.8 kg increase. Transient nausea was the most common adverse event.1
Limitations
HbA1c and body weight are distinct from long-term complication outcomes. The abstract does not replace the full hypoglycemia analysis or label warnings.1
Reviewed study record
Type 2 diabetes: year-long adjunctive trial
Design
Randomized, double-blind, placebo-controlled trial over 52 weeks in insulin-treated patients.2
One active group had a 0.62 percentage-point HbA1c reduction at week 52 and weight change of −1.4 kg versus +0.7 kg with placebo. The authors reported no overall increase in severe-hypoglycemia rate; nausea was common.2
Limitations
A trial-wide hypoglycemia result does not negate regimen-specific risk or current boxed warnings. The report concerns selected insulin-treated patients.2
Reviewed study record
Experimental automated delivery
Design
Randomized crossover comparison of three automated-delivery approaches, each studied for 14 days.3
Population
32 participants enrolled; 30 completing all interventions were analyzed, including 15 adults and 15 adolescents.3
Outcomes reported
The insulin-and-pramlintide system with simple meal announcements met the prespecified glucose-control noninferiority comparison but did not improve emotional burden. Gastrointestinal symptoms occurred more often with pramlintide; no serious adverse events occurred.3
Limitations
The small, short crossover trial excluded noncompleters from the primary analysis. It evaluates a combined device-and-drug approach and cannot establish longer-term safety or a broader approved indication.3
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1111/j.1464-5491.2004.01319.x. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.2337/diacare.26.3.784. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s2589-7500(24)00092-x. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗